Diagnostic Solutions was Qiagen’s largest product and service line in fiscal 2025, bringing in $803.08M of $2.09B (38%).
| Product and Service | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumables & Related | — | — | — | — | ||||||||||||||
| Consumables & Related Revenues | — | — | — | — | ||||||||||||||
| Sample Technologies | $796.93M | $662.99M | $642.03M | $661.27M | ||||||||||||||
| Diagnostic Solutions | $660.88M | $697.63M | $748.89M | $803.08M | ||||||||||||||
| Pcr/Nucleic Acid Amplification | — | $300.20M | $300.47M | $308.99M | ||||||||||||||
| Pcr / Nucleic Acid Amplification | $390.80M | — | — | — | ||||||||||||||
| Genomics/Ngs | — | $238.91M | $233.61M | $241.78M | ||||||||||||||
| Genomics / Ngs | $224.80M | — | — | — | ||||||||||||||
| Instruments | — | — | — | — | ||||||||||||||
| Instrumentation | — | — | — | — | ||||||||||||||
| Other | $68.11M | $65.58M | $53.22M | $74.89M | ||||||||||||||
| Total | $2.14B | $1.97B | $1.98B | $2.09B |
Qiagen brought in $2.09B from its five product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 5.7% from $1.98B in fiscal 2024. Diagnostic Solutions was the largest at $803.08M (38.4%), ahead of Sample Technologies at $661.27M (31.6%) and Pcr/Nucleic Acid Amplification at $308.99M (14.8%). The other two lines brought in $316.66M combined.
Compared with fiscal 2024, Other grew fastest, up 40.7% to $74.89M. Every line above 2% of revenue grew.
Qiagen began breaking out Pcr/Nucleic Acid Amplification in fiscal 2023 and Genomics/Ngs in fiscal 2023. Qiagen stopped reporting Pcr / Nucleic Acid Amplification ($390.80M in fiscal 2022) and Genomics / Ngs ($224.80M in fiscal 2022) as separate lines.
United States was Qiagen’s largest region in fiscal 2025, bringing in $998.45M of $2.09B (48%).
| Geography | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $909.62M | $935.28M | $942.01M | $998.45M | ||||||||||||||
| Europe, Middle East & Africa | $733.47M | $624.57M | $648.49M | $712.76M | ||||||||||||||
| Emea | — | — | — | — | ||||||||||||||
| Europe | — | — | — | — | ||||||||||||||
| Asia Pacific, Japan & Rest Of World | $410.29M | $320.68M | $298.15M | $290.73M | ||||||||||||||
| Asia Pacific & Rest Of World | — | — | — | — | ||||||||||||||
| Other Americas | $88.14M | $84.77M | $89.56M | $88.07M | ||||||||||||||
| The Netherlands | — | — | — | — | ||||||||||||||
| Total | $2.14B | $1.97B | $1.98B | $2.09B |
Qiagen brought in $2.09B from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 5.7% from $1.98B in fiscal 2024. United States was the largest at $998.45M (47.8%), ahead of Europe, Middle East & Africa at $712.76M (34.1%) and Asia Pacific, Japan & Rest Of World at $290.73M (13.9%). The remaining region, Other Americas, brought in $88.07M.
Compared with fiscal 2024, Europe, Middle East & Africa grew fastest, up 9.9% to $712.76M, while Asia Pacific, Japan & Rest Of World fell the most, down 2.5% to $290.73M. From fiscal 2022 to 2025, combined revenue from these regions fell from $2.14B to $2.09B, a compound annual decline of 0.8%. United States' share of the total rose from 42.5% to 47.8%.
Molecular Diagnostics was Qiagen’s largest revenue line in fiscal 2022, bringing in $1.13B of $2.14B (53%).
| Customer | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|---|---|---|---|
| Life Sciences | $789.29M | $966.37M | $1.11B | $1.02B | |||
| Molecular Diagnostics | $737.13M | $903.98M | $1.14B | $1.13B | |||
| Academia / Applied Testing | — | — | — | — | |||
| Academia | — | — | — | — | |||
| Pharma | — | — | — | — | |||
| Applied Testing | — | — | — | — | |||
| Total | $1.53B | $1.87B | $2.25B | $2.14B |
Qiagen brought in $2.14B from its two revenue lines in fiscal 2022, the year ended December 31, 2022. That was down 4.9% from $2.25B in fiscal 2021. Molecular Diagnostics was the largest at $1.13B (52.6%), ahead of Life Sciences at $1.02B (47.4%).
Compared with fiscal 2021, Molecular Diagnostics fell 1.5% to $1.13B and Life Sciences fell 8.4% to $1.02B. From fiscal 2019 to 2022, combined revenue from these revenue lines grew from $1.53B to $2.14B, a compound annual growth rate of 11.9%. Molecular Diagnostics' share of the total rose from 48.3% to 52.6%.
Qiagen (QGEN) reports its revenue by product and service, by geography and by customer. In fiscal 2025, Diagnostic Solutions was its largest product and service line, bringing in $803.08M (38.4% of the total), followed by Sample Technologies at $661.27M (31.6%).
Diagnostic Solutions was Qiagen's largest product and service line in fiscal 2025, bringing in $803.08M, or 38.4% of the $2.09B total across its five product and service lines.
United States was Qiagen's largest region in fiscal 2025, bringing in $998.45M, or 47.8% of the $2.09B total across its four regions.
Molecular Diagnostics was Qiagen's largest revenue line in fiscal 2022, bringing in $1.13B, or 52.6% of the $2.14B total across its two revenue lines.
Among Qiagen's product and service lines that make up at least 2% of revenue, Other grew fastest in fiscal 2025, up 40.7% from $53.22M to $74.89M.
Every figure comes from Qiagen's annual financial filings, as reported. Each line keeps the name Qiagen gives it, and years follow its fiscal calendar.
Qiagen's revenue by product and service goes back to fiscal 2008, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.